Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

3.82
Delayed Data
As of 10:45am ET
 +0.09 / +2.41%
Today’s Change
3.44
Today|||52-Week Range
11.74
-45.43%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$73.6M

Company Description

Conatus Pharmaceuticals, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel medicines to treat liver diseases. It develops lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, Steven J. Mento and Charles J. Cashion on July 13, 2005 and is headquartered in San Diego, CA.

Contact Information

Conatus Pharmaceuticals, Inc.
16745 West Bernardo Drive
San Diego California 92127
P:(858) 376-2600
Investor Relations:
(858) 376-2637

Employees

Shareholders

Individual stakeholders39.08%
Other institutional19.93%
Mutual fund holders11.92%

Top Executives

Steven J. MentoPresident, Chief Executive Officer & Director
Charles J. CashionChief Financial Officer, Secretary & SVP
Alfred P. SpadaCSO, Executive VP-Research & Development
Daniel L. RipleyVP-Business Development & Program Management
David T. HagertyExecutive Vice President-Clinical Development